It struck me that NEOT was at the top of the heap this week and GNLB close to the bottom. Not too long ago it was just the opposite.
I still feel that the volitility in biotech has nothing to do with the quality of the companies. It is simply the MM's bringing them up and down to squeeze out their cut and increase inventory for the big push to come.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.